Skip to content
Easy Peptide Info
Menu
Research peptide

What is CJC-1295?

CJC-1295 explained in plain English: what it is, what the research shows, side effects, legal status and dosage, plus a calculator for syringe units. Doses shown come only from the label or published trials, each with its source. Also called CJC-1295 DAC, Mod GRF 1-29, CJC.

CJC-1295 is not approved for human use by the FDA or any other regulator. This page is educational; talk with a qualified healthcare professional before using any substance.

Calculate
Vial unit

= 2,000 mcg

mL
Dose unit
Syringe type
Syringe size

Units to draw

–units

Enter your dose.

Syringe, no result yetU-100, 1 mL syringe holding up to 100 units. Enter your dose.0102030405060708090100

Saved calculations

No saved calculations yet. Save one from the results.

What is CJC-1295?

CJC-1295 is a lab-made copy of GHRH (growth hormone-releasing hormone), the brain hormone that tells the pituitary gland to release growth hormone. It was developed by the Canadian company ConjuChem in the early 2000s.

The original version has a “DAC” (drug affinity complex) that binds to a blood protein, so one injection lasts for days. A version without DAC, often sold as Mod GRF 1-29, is short-acting.

What does CJC-1295 do?

CJC-1295 raises the body’s own growth hormone and IGF-1, the hormone growth hormone works through. People use it hoping for fat loss, muscle, better sleep and recovery, often combined with ipamorelin.

Those hoped-for effects come from what growth hormone does in general, not from trials of CJC-1295.

What does the research on CJC-1295 show?

In a 2006 study in healthy adults, a single injection of CJC-1295 with DAC raised growth hormone two- to ten-fold for six days or more, and IGF-1 for over a week. That showed it works as intended on hormone levels.

Development stopped after a participant in a later trial died; the death was reported as unrelated to the drug, but CJC-1295 never went further. No trial has shown it improves body composition, health or aging in people.

CJC-1295 side effects and risks

Reported side effects include flushing, headache, injection-site reactions, water retention and a racing heart. The FDA noted increased heart rate and whole-body flushing reactions among its safety concerns.

Keeping growth hormone and IGF-1 high for long periods may raise blood sugar and, in theory, affect cancer risk; the long-term effects are unknown. Products sold online aren’t checked for purity or strength.

CJC-1295 is not approved for human use by the FDA or any other regulator. It was placed on the FDA’s list of compounding substances with safety concerns in 2023 and moved off it in 2024 after its nomination was withdrawn, which is not an approval.

It is banned at all times by the World Anti-Doping Agency.

How do you reconstitute CJC-1295?

CJC-1295 comes as a powder that is mixed with bacteriostatic water. The calculator above turns the vial size, the water and a dose into syringe units, and the reconstitution guide explains each step.

See the dosage section below for what is known about doses, with sources.

CJC-1295 dosage in clinical trials

CJC-1295 is not approved. The only published human dosing study gave healthy adults a single injection dosed by body weight; at the two highest doses, IGF-1 rose above the normal range in some people.

Doses tested in published clinical trials. They are not approved doses, and trial participants were closely monitored.

CJC-1295 doses, with sources
WhenDoseHow often
Phase 1 trial, single injection (CJC-1295 with DAC)30, 60, 125 or 250 mcg/kg[1]Once
  1. Teichman et al. (2006), CJC-1295 in healthy adults, J Clin Endocrinol Metab

Medical disclaimer: this dosage information is for education only and comes from the source shown for each row. It is not medical advice and not a recommendation for you. Only a licensed prescriber who knows your health can decide whether CJC-1295 is right for you and at what dose. Don't start, change or stop a medicine based on this page, and don't use research peptides or unapproved drugs based on trial doses.

CJC-1295 concentration chart

The concentration of a CJC-1295 vial depends only on its size and the water you add. Each unit on a U-100 syringe holds one hundredth of a mL.

CJC-1295 concentration by vial size and water
Vial + waterConcentrationPer unit (U-100)
2 mg + 1 mL2,000 mcg/mL (2 mg/mL)20 mcg per unit (0.02 mg per unit)
2 mg + 2 mL1,000 mcg/mL (1 mg/mL)10 mcg per unit (0.01 mg per unit)
2 mg + 3 mL666.67 mcg/mL (0.66667 mg/mL)6.67 mcg per unit (0.00667 mg per unit)
5 mg + 1 mL5,000 mcg/mL (5 mg/mL)50 mcg per unit (0.05 mg per unit)
5 mg + 2 mL2,500 mcg/mL (2.5 mg/mL)25 mcg per unit (0.025 mg per unit)
5 mg + 3 mL1,666.67 mcg/mL (1.66667 mg/mL)16.67 mcg per unit (0.01667 mg per unit)

Frequently asked questions

What is the difference between CJC-1295 with and without DAC?

DAC (drug affinity complex) lets the peptide attach to albumin in the blood, so it lasts for days. CJC-1295 without DAC, also sold as Mod GRF 1-29, lasts well under an hour.

Why is CJC-1295 taken with ipamorelin?

Users pair a GHRH analog (CJC-1295) with a ghrelin-type peptide (ipamorelin) because the two trigger growth hormone through different receptors. The pairing has never been tested in clinical trials.

Is CJC-1295 banned in sport?

Yes. The World Anti-Doping Agency bans growth hormone-releasing factors like CJC-1295 at all times.

Sources

  1. Teichman et al. (2006), Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults, J Clin Endocrinol Metab
  2. FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
  3. World Anti-Doping Agency, The Prohibited List

Last updated .

More peptide guides and calculators